Enanta Pharmaceuticals, Inc.
ENTA
$13.24
-$0.26-1.93%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 0.70% | 7.37% | 0.58% | -3.42% | -9.94% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 0.70% | 7.37% | 0.58% | -3.42% | -9.94% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 0.70% | 7.37% | 0.58% | -3.42% | -9.94% |
| SG&A Expenses | -21.22% | -25.43% | -25.99% | -24.06% | -17.34% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -23.29% | -22.20% | -20.85% | -20.42% | -17.04% |
| Operating Income | 39.34% | 40.86% | 33.79% | 29.86% | 21.20% |
| Income Before Tax | 32.89% | 37.42% | 31.66% | 29.07% | 20.36% |
| Income Tax Expenses | 104.82% | 103.71% | 20.62% | 4.76% | 26.34% |
| Earnings from Continuing Operations | 31.28% | 35.71% | 31.82% | 29.43% | 20.22% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 31.28% | 35.71% | 31.82% | 29.43% | 20.22% |
| EBIT | 39.34% | 40.86% | 33.79% | 29.86% | 21.20% |
| EBITDA | 42.15% | 43.96% | 36.78% | 32.33% | 22.69% |
| EPS Basic | 44.24% | 42.85% | 35.29% | 30.03% | 20.82% |
| Normalized Basic EPS | 44.88% | 43.74% | 34.55% | 29.95% | 22.19% |
| EPS Diluted | 44.24% | 42.85% | 35.29% | 30.03% | 20.82% |
| Normalized Diluted EPS | 44.88% | 43.74% | 34.55% | 29.95% | 22.19% |
| Average Basic Shares Outstanding | 27.12% | 18.34% | 9.54% | 0.86% | 0.79% |
| Average Diluted Shares Outstanding | 27.12% | 18.34% | 9.54% | 0.86% | 0.79% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |